Intangible Finance — Lesson 9 of 10
Theory is essential, but intangible finance is ultimately a practical discipline. The structures, risks, and opportunities we have examined across this programme are best understood through the lens of transactions that have actually been executed — their rationale, their structures, their outcomes, and the lessons they provide for future practitioners.
This lesson analyses four landmark intangible finance transactions, each representing a different pillar of the market. Together, they demonstrate the breadth of intangible finance and the ingenuity of the structuring solutions that have been developed.
Each of these case studies demonstrates a common principle: intangible finance works best when the underlying asset has identifiable, predictable cash flows and when the structure is designed to address the specific risks of that asset type. The Bowie Bonds worked because music royalties are contractual and predictable. Royalty Pharma works because pharmaceutical patents have defined terms and licensing agreements with minimum commitments. The Kyndryl transaction worked because the IP had immediate, identifiable revenue attribution. Structures that attempt to securitise vague or unquantified intangible value — without clear cash flow attachment — have consistently failed.
Case Study 1: Bowie Bonds — The Pioneer
Background
In January 1997, David Bowie issued $55 million in asset-backed securities secured by the future royalty income from his first 25 albums (287 songs recorded before 1990). The bonds paid a coupon of 7.9% and had a 10-year maturity. Prudential Insurance Company purchased the entire issue.
The transaction was structured by David Pullman of Pullman & Company, and it established the template for all subsequent intellectual property securitisations.
Structure
| Component | Detail |
|---|---|
| Issuer | SPV holding rights to Bowie's pre-1990 catalogue royalties |
| Underlying assets | Future royalty income from 287 songs across 25 albums |
| Notes | $55 million, 10-year maturity, 7.9% annual coupon |
| Credit enhancement | EMI guaranteed minimum royalty payments; overcollateralisation |
| Rating | Moody's A3 (investment grade) at issuance |
| Buyer | Prudential Insurance Company (private placement) |
Outcome and Lessons
The Bowie Bonds paid in full at maturity in 2007, validating the structure. However, the journey was not smooth. In 2004, Moody's downgraded the bonds to Baa3 (one notch above junk) as music industry revenues declined sharply due to digital disruption and illegal file-sharing. The downgrade illustrated a critical risk: the underlying intangible assets — music copyrights — were subject to industry-level disruption that the original structuring did not fully contemplate.
The Bowie Bonds case illustrates the "platform risk" inherent in intangible asset securitisation. Bowie's songs did not become less popular after 2000 — but the revenue model for music changed fundamentally. Streaming replaced purchases; per-play royalty rates were a fraction of CD sales royalties. The asset was still valuable, but the cash flow profile changed dramatically. Any intangible finance structure must stress-test against platform or industry disruption — not just against the asset's specific performance. The best structures include technology refresh covenants, revenue model diversification, and platform risk triggers.
Case Study 2: Royalty Pharma — Institutional Scale
Background
Royalty Pharma, founded in 1996 and publicly listed in 2020, is the world's largest buyer of biopharmaceutical royalty streams. As of 2024, the company's portfolio includes royalties on 35+ approved and marketed therapies, generating over $2.5 billion in annual royalty receipts.
Royalty Pharma represents the evolution from bilateral IP transactions (like Bowie Bonds) to an institutional-scale, permanent capital vehicle for intangible finance.
Continue reading — free
Sign up in seconds to unlock all lessons, quizzes, and your personalised learning dashboard. No credit card required.
Already have an account? Log in
By continuing you agree to our Terms and Privacy Policy.